<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Mundipharma Pte Ltd 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=32567></link><description><![CDATA[Mundipharma Pte Ltd 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 03 May 2026 01:58:49 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2020/01/12_3554238800_20200121085913_2888639377.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Laboratory Studies Confirm BETADINE® Antiseptic Products’ Effectiveness Against COVID-19 Virus]]></title><link>https://www.newswire.co.kr/newsRead.php?no=907683</link><description><![CDATA[SINGAPORE--(Business Wire/Korea Newswire)--Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE® antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease.  Testing has demonstrated BETADINE’s® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 ...]]></description><pubDate>Fri, 10 Jul 2020 17:25:00 +0900</pubDate></item><item><title><![CDATA[베타딘 소독제품들, 실험실 연구서 코로나19에 대한 항바이러스 효과 확인]]></title><link>https://www.newswire.co.kr/newsRead.php?no=907684</link><description><![CDATA[싱가포르--(Business Wire/뉴스와이어)--싱가포르 소재 듀크-NUS 의과대학원(Duke-NUS Medical School)이 실시한 실험실 검사에서 베타딘(BETADINE®) 소독제가 코로나바이러스 감염증-19(COVID-19; 이하 ‘코로나19’)를 유발하는 신종 코로나바이러스(SARS-CoV-2)에 대한 항바이러스 효과가 있는 것이 확인됐다고 먼디파마(Mundipharma)가 9일 발표했다.   베타딘은 검사에서 SARS-CoV-2 바이러스를 30초 만에 99.99...]]></description><pubDate>Fri, 10 Jul 2020 17:25:00 +0900</pubDate></item><item><title><![CDATA[Marc Princen appointed new Global CEO for Mundipharma]]></title><link>https://www.newswire.co.kr/newsRead.php?no=906379</link><description><![CDATA[CAMBRIDGE, England--(Business Wire/Korea Newswire)--FOR MEDICAL BUSINESS/TRADE MEDIA ONLY  Mundipharma announced today that Marc Princen has joined the Mundipharma network of independently associated companies as the Global Chief Executive Officer, effective June 1, 2020. In his new role, Princen will be responsible for all Mundipharma strategic and operational matters globally, focusing on seaml...]]></description><pubDate>Mon, 15 Jun 2020 16:43:28 +0900</pubDate></item><item><title><![CDATA[‘베타딘’ 소독제의 신종 코로나바이러스(SARS-CoV-2) 예방에 대한 효과 평가 진행]]></title><link>https://www.newswire.co.kr/newsRead.php?no=904063</link><description><![CDATA[싱가포르--(Business Wire/뉴스와이어)--먼디파마(Mundipharma)가 코로나바이러스 증후군(COVID-19)의 원인이 되는 신종 코로나바이러스(SARS-CoV-2) 예방을 위한 자사 소독제인 ‘베타딘(BETADINE® )’ 제품의 효과를 평가하는 일련의 체외 및 체내 연구에 착수한다고 21일 발표했다.  BLS3실험실과 아시아, 유럽 및 미국의 전문가들이 협력하여 검사를 진행할 예정이다.            현재 전 세계적으로 수요가 높은...]]></description><pubDate>Wed, 22 Apr 2020 13:43:47 +0900</pubDate></item><item><title><![CDATA[Evaluate BETADINE® Antiseptic Products’ Effectiveness Against SARS-CoV-2]]></title><link>https://www.newswire.co.kr/newsRead.php?no=904061</link><description><![CDATA[SINGAPORE--(Business Wire/Korea Newswire)--Mundipharma today announced that it will embark on an ambitious series of studies both in vitro and in vivo to evaluate the effectiveness of its BETADINE® antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. Testing will be initiated in collaboration with BLS3 laboratories and experts in Asia, Europe and ...]]></description><pubDate>Wed, 22 Apr 2020 13:35:20 +0900</pubDate></item><item><title><![CDATA[먼디파마, 삼성바이오에피스와 파트너십 체결… 홍콩, 대만 시장으로 바이오시밀러 확대 목적]]></title><link>https://www.newswire.co.kr/newsRead.php?no=900295</link><description><![CDATA[싱가포르--(Business Wire/뉴스와이어)--먼디파마(Mundipharma)가 삼성바이오에피스와 파트너십을 체결했다고 16일 발표했다.  이에 따라 양사는 대만과 홍콩에서 삼성바이오에피스의 바이오시밀러 후보물질을 상용화하는 데 협력하게 된다.  이번 파트너십은 삼성바이오에피스의 면역학 및 종양학 분야 바이오시밀러 후보물질이 대상이며 SB5(아달리무맙), SB4(에타너셉트), SB3(트라스투주맙), SB8(베카시주맙)이...]]></description><pubDate>Tue, 21 Jan 2020 11:17:41 +0900</pubDate></item><item><title><![CDATA[Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan]]></title><link>https://www.newswire.co.kr/newsRead.php?no=900291</link><description><![CDATA[SINGAPORE--(Business Wire/Korea Newswire)--Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.  The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab). ...]]></description><pubDate>Tue, 21 Jan 2020 10:41:27 +0900</pubDate></item><item><title><![CDATA[Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=883893</link><description><![CDATA[BASEL, Switzerland--(Business Wire/Korea Newswire)--Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cho...]]></description><pubDate>Mon, 25 Feb 2019 09:50:00 +0900</pubDate></item></channel></rss>